Loading stock data…
Apogee Therapeutics (APGE)
$135.07
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apogee Therapeutics, Inc. in the Healthcare sector is trading at $135.07 with a market capitalization of $6.4B. Wall Street consensus targets $134.62 (5 analysts), implying a -0.3% move over the next 12 months. The stock is currently near its 52-week high of $135.09, remaining 72.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$82.77M↓ | -$78.06M↓ | -$71.28M↑ | -$73.17M↓ | -$63.10M |
| Net Income | -$74.11M↓ | -$69.39M↓ | -$65.02M↑ | -$66.10M↓ | -$55.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.87%
Volume
Today's trading volume
0
Recent News
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?
What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
AbbVie Defends Its Turf, But Leaves One Big Question Open
AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.